NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

50:05 - 55:30. Key phrases in LL interview.

Paraphrasing from her hypotheticals regarding what might be efficacy but might not allow approval:

No median statistical separation

but 25% tail (heard that before?)

and yet 36 month all control dead (remember Dr. Bosch pointing out importance of 36 months, remember the 36 month to 88 month phenomenon, remember blinded chart ends at 36 moths?)

20% to 30% of treatment patients living a long time. (heard that before?)

Pharmaceutical companies unblind too early.

tail end of survival curve 3,4,5 years out

Trials aren't currently designed to reflect that (heard that before?)

(Just sayin, the similarities are uncanny)


To be fair, when she immediately thereafter discussed DCVax-L, she basically stated she was looking forward to the unblinding so she could analyze responders and non responders more in depth.